v3.26.1
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details)
1 Months Ended 12 Months Ended
Jun. 10, 2024
USD ($)
Jun. 10, 2024
EUR (€)
Nov. 30, 2020
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Aug. 31, 2024
USD ($)
Dec. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
May 31, 2022
USD ($)
Nov. 30, 2021
USD ($)
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Research and development       $ 9,802,807 $ 3,602,632          
Accrued research and development expense       934,524 183,094          
Therapeutics Inc.                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Initial term     3 years              
Written termination notice period     90 days              
Total amount of agreement           $ 3,600,000 $ 830,000 $ 4,400,000    
Research and development       2,100,000 1,100,000          
Credit of prior expenses incurred         $ 83,000          
Netherton Syndrome                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Total amount of agreement                   $ 250,000
Scleroderma                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Total amount of agreement                 $ 610,000  
The School of Pharmacy at UCC                    
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS                    
Maximum funding amount $ 664,000 € 567,000                
Commitment period 2 years 6 months 2 years 6 months                
Accrued research and development expense       $ 300,000